Today’s Most Active Stock are (HDY, DUSA, PARD) - Stock Update

Penny Stock Pick Report alerts investors on Top Stocks that can helps investors in getting high returns. Subscribe to our FREE Stock Alerts by visiting: http://www.PennyStockPickReport.com
 

Hyperdynamics Corporation (AMEX:HDY) augmented 10.90% to $1.73 on unusual volume of 637k shares compared to a daily trading average of 293k shares after it announced that it has signed a letter of intent with Scotland-based Dana Petroleum plc (LSE:DNX) for a 23% participating interest in Hyperdynamics' oil and gas concession offshore the Republic of Guinea in exchange for total consideration of USD20m. The stock has a 52-week range of $0.22-$1.92. So far in the last six months the stock has rallied over 616%. Hyperdynamics Corporation (Hyperdynamics) is an oil and gas exploration and production company. The Company has certain contract rights for the exploration and exploitation of oil and gas in an approximately 80,000 square kilometer concession off the coast of the Republic of Guinea (Guinea) in West Africa. The Company is engaged in oil and gas exploration off the coast of Guinea through its wholly owned subsidiary, SCS Corporation (SCS).

DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) zoomed 22.56% to $1.63 on an unusual huge volume of 341k shares compared to a daily average trading of 72k shares on no news. The stock has a 52-week range of $0.87-$1.80. The stock today also created a new 52-week high at $1.80. DUSA Pharmaceuticals, Inc. (DUSA) is a vertically integrated dermatology company developing and marketing Levulan PDT and other products for common skin conditions. The marketed products include among others Levulan Kerastick 20% Topical Solution with photodynamic therapy (PDT), the BLU-U brand light source, and certain products, including ClindaReach. In addition to the marketed products, the drug, Levulan brand of aminolevulinic acid (ALA) HCl.

Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) added $0.41 or 5.97% over its previous day’s price and now trades at $7.28 on a huge volume of 497k shares. The stock has a 52-week range of $1.05-$9.14. So far in the last six months the stock has rallied over 226%. Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of cancer therapy products. Its lead product candidate is picoplatin, a platinum-based cancer therapy. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance in the treatment of solid tumors.